Takeda Pharmaceutical Company's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; and it has a dividend yield of 4.30%. Takeda Pharmaceutical Company is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is

lt;0.01. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22
Income Statement	-
Total Revenue	-	¥ 1.10T	¥ 1.00T	¥ 972.47B	¥ 873.29B
Gross Profit	-	¥ 760.58B	¥ 696.86B	¥ 679.58B	¥ 564.91B
EBIT	-	¥ 186.90B	¥ 118.35B	¥ 210.94B	¥ -75.15B
EBITDA	-	¥ 363.78B	¥ 286.18B	¥ 369.23B	¥ 77.12B
Net Income Common Stockholders	-	¥ 119.13B	¥ 61.74B	¥ 105.01B	¥ -11.36B
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	¥ 632.70B	¥ 726.61B	¥ 830.07B	¥ 664.53B	¥ 875.00B
Total Assets	¥ 13.96T	¥ 13.50T	¥ 14.59T	¥ 14.07T	¥ 13.18T
Total Debt	¥ 4.38T	¥ 4.29T	¥ 4.74T	¥ 4.60T	¥ 4.35T
Net Debt	¥ 3.75T	¥ 3.56T	¥ 3.91T	¥ 3.94T	¥ 3.47T
Total Liabilities	¥ 9.28T	¥ 7.33T	¥ 7.88T	¥ 7.75T	¥ 7.49T
Stockholders Equity	¥ 4.68T	¥ 6.18T	¥ 6.71T	¥ 6.32T	¥ 5.68T
Cash Flow	-
Free Cash Flow	-	¥ 327.61B	¥ 180.38B	¥ -14.13B	¥ 323.76B
Operating Cash Flow	-	¥ 378.23B	¥ 220.99B	¥ 84.24B	¥ 375.58B
Investing Cash Flow	-	¥ -46.69B	¥ -27.21B	¥ -94.71B	¥ -25.64B
Financing Cash Flow	-	¥ -434.95B	¥ -51.88B	¥ -215.72B	¥ -243.80B

Currency in JPY

Takeda Pharmaceutical Company Earnings and Revenue History

Income Statement >

Takeda Pharmaceutical Company Debt to Assets

Balance Sheet >

Takeda Pharmaceutical Company Cash Flow

Cash Flow >

Takeda Pharmaceutical Company Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing